1 day Ago By ABMN Staff
Bank of New York Mellon Corp grew its stake in shares of Dr. Reddy’s Laboratories Limited ( NYSE:RDY – Free Report ) by 1.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC).
The fund owned 26,768 shares of the company’s stock after acquiring an additional 489 shares during the quarter. Bank of New York Mellon Corp’s holdings in Dr. Reddy’s Laboratories were worth $2,040,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. GAMMA Investing LLC grew its holdings in shares of Dr. Reddy’s Laboratories by 54.
7% during the 1st quarter. GAMMA Investing LLC now owns 721 shares of the company’s stock worth $53,000 after purchasing an additional 255 shares during the period. Contravisory Investment Management Inc.
purchased a new position in Dr. Reddy’s Laboratories in the 1st quarter worth approximately $189,000. CWM LLC boosted its holdings in Dr.
Reddy’s Laboratories by 18.9% in the 1st quarter. CWM LLC now owns 2,584 shares of the company’s stock worth $190,000 after acquiring an additional 410 shares during the period.
Legacy Capital Group California Inc. purchased a new position in Dr. Reddy’s Laboratories in the 2nd quarter worth approximately $204,000.
Finally, Aprio Wealth Management LLC purchased a new position in Dr. Reddy’s Laboratories in the 1st quarter worth approximately $212,000. Institutional investors and hedge funds own 14.
02% of the company’s stock. Analysts Set New Price Targets Separately, Barclays increased their target price on Dr. Reddy’s Laboratories from $81.
00 to $87.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. Dr.
Reddy’s Laboratories Stock Down 0.2 % Shares of Dr. Reddy’s Laboratories stock opened at $79.
51 on Wednesday. The stock has a 50-day moving average price of $81.14 and a 200 day moving average price of $75.
63. The company has a market cap of $13.27 billion, a P/E ratio of 19.
75, a P/E/G ratio of 1.74 and a beta of 0.55.
The company has a current ratio of 2.55, a quick ratio of 1.90 and a debt-to-equity ratio of 0.
02. Dr. Reddy’s Laboratories Limited has a 1 year low of $63.
72 and a 1 year high of $84.46. Dr.
Reddy’s Laboratories ( NYSE:RDY – Get Free Report ) last posted its quarterly earnings results on Saturday, July 27th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.
10 by ($0.10). Dr.
Reddy’s Laboratories had a return on equity of 20.32% and a net margin of 19.28%.
The firm had revenue of $919.80 million for the quarter, compared to analysts’ expectations of $861.68 million.
As a group, analysts expect that Dr. Reddy’s Laboratories Limited will post 4.11 EPS for the current fiscal year.
Dr. Reddy’s Laboratories Company Profile ( Free Report ) Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.
It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. Read More Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Dr. Reddy’s Laboratories Limited ( NYSE:RDY – Free Report ). Receive News & Ratings for Dr.
Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter .
.
